PharmaBlock Sciences Nanjing Inc Class A

PharmaBlock Sciences Nanjing Inc Class A

300725 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

43.40CNY-2.42 (-5.28%)

Price History

Full chart

Market Stats

Previous Close45.82
Open45.38
Day Range43.18 – 45.70
52-Week Range30.67 – 57.55
Volume19.56M
Market Cap12.94B
P/E (TTM)58.26
Forward P/E0.00
EPS0.95
Dividend Yield0.69%
Beta0.55
50-Day Avg45.89
200-Day Avg40.24

About

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Minmin Yang Ph.D.
  • Employees2.59K
  • HeadquartersNo. 81, Huasheng Road, Nanjing, China, 210032, China
  • Websitehttps://www.pharmablock.com

Leadership

  • Dr. Minmin Yang Ph.D.Co-Founder, Chairman & CEO · b. 1972
  • Ms. Juanjuan WuCFO & Director · b. 1977
  • Mr. Shanbao YuSecretary of the Board · b. 1982
  • Dr. Shuhai Zhao Ph.D.Co-founder & Chief Scientific Officer · b. 1963
  • Dr. David Chen Ph.D.Executive VP, Chief Operation Officer & Head of CDMO
  • Dr. Shijie Zhang Ph.D.Chief Technology Officer · b. 1964
  • Dr. Dezhi Sha Ph.D.Sr. VP of Process Technology & Manufacturing
  • Dr. Jing Li Ph.D.Sr. VP of Process Chemistry & President of PharmaBlock (USA), Inc. · b. 1973

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue58.55M76.64M136.13M188.38M273.25M478.25M662.23M1.02B1.20B1.59B1.73B1.69B1.97B
Growth (%)-+30.90%+77.63%+38.38%+45.05%+75.02%+38.47%+54.36%+17.55%+32.71%+8.18%-2.12%+16.93%
Cost of Revenue18.08M26.22M53.59M67.44M106.05M208.95M324.67M556.44M632.85M878.71M1.02B1.11B1.37B
Gross Profit40.47M50.42M82.54M120.94M167.20M269.30M337.56M465.79M568.78M715.99M707.20M582.74M608.45M
Gross Margin69.12%65.79%60.63%64.20%61.19%56.31%50.97%45.57%47.33%44.90%40.99%34.51%30.82%
Operating Expense19.91M25.77M58.40M80.16M93.08M126.33M174.02M271.66M75.83M419.28M522.60M331.54M353.83M
Operating Income20.56M24.65M24.14M40.77M74.12M142.98M163.54M194.13M492.96M296.71M184.60M251.20M254.62M
Operating Margin35.11%32.16%17.73%21.64%27.13%29.90%24.69%18.99%41.02%18.61%10.70%14.88%12.90%
EBITDA25.15M29.85M31.14M53.43M89.65M172.31M197.33M229.69M571.67M456.15M403.87M439.94M381.61M
EBITDA Margin42.95%38.95%22.88%28.36%32.81%36.03%29.80%22.47%47.57%28.60%23.41%26.05%19.33%
Net Income18.25M22.47M19.93M36.12M67.18M133.36M152.07M184.21M486.56M314.22M197.36M219.54M183.74M
Net Income Margin31.17%29.32%14.64%19.17%24.59%27.89%22.96%18.02%40.49%19.70%11.44%13.00%9.31%
R&D6.96M7.45M8.99M16.31M24.73M44.35M69.22M90.93M114.02M168.32M169.17M107.33M108.72M
R&D as % of Total Revenue11.88%9.72%6.60%8.66%9.05%9.27%10.45%8.89%9.49%10.56%9.81%6.36%5.51%
Interest Expense448.57K-9.70K225.66K269.49K1.00M3.87M706.05K10.69M46.64M68.20M62.28M34.22M
Interest Expense % of Total Revenue0.77%-0.01%0.12%0.10%0.21%0.58%0.07%0.89%2.92%3.95%3.69%1.73%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets85.13M101.56M172.48M299.15M567.40M761.16M1.03B2.43B3.51B4.86B5.10B4.94B7.34B
Total Liabilities14.97M14.38M25.92M45.00M63.80M161.43M288.27M530.57M879.21M2.20B2.27B1.95B1.04B
Total Equity70.00M87.04M145.70M245.30M495.26M599.73M740.87M1.89B2.43B2.66B2.83B2.99B6.30B
Cash19.41M13.87M61.18M78.05M157.56M265.78M163.58M1.24B699.63M1.15B511.19M290.20M532.74M
Total Debt---3.80M298.99K25.22M60.36M120.44M381.02M1.57B1.75B1.36B-
Net Debt-19.41M-13.87M-61.18M-74.25M-157.26M-240.55M-103.22M-1.12B-318.61M422.64M1.24B1.07B-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow18.32M11.91M27.52M22.76M54.64M160.16M127.04M271.51M238.03M246.61M246.84M302.82M667.36M
Investing Cash Flow-6.70M-10.59M-3.75M-59.10M-153.87M-39.10M-300.67M-144.58M-914.34M-593.64M-943.78M-76.11M-
Financing Cash Flow-2.29M-6.85M21.89M49.69M182.48M-19.45M51.10M992.67M145.22M760.36M65.37M-468.96M-
Capital Expenditure6.23M9.48M9.70M38.26M49.06M48.44M173.52M75.18M505.76M557.91M315.77M118.12M140.13M
Free Cash Flow12.08M2.43M17.82M-15.51M5.58M111.72M-46.48M196.33M-267.73M-311.30M-68.93M184.70M527.23M
Dividends Paid448.57K6.85M10.01M507.70K61.00K15.67M22.00M21.72M15.36M19.97M19.97M77.97M65.75M
FCF to OCF65.97%20.41%64.75%-68.13%10.21%69.76%-36.58%72.31%-112.48%-126.23%-27.93%60.99%79.00%
Dividend Paid to FCF3.71%281.99%56.17%-3.27%1.09%14.02%-47.34%11.06%-5.74%-6.41%-28.96%42.22%12.47%

Earnings

Report DateMar 14, 2018Apr 26, 2018Aug 28, 2018Oct 26, 2018Feb 25, 2019Apr 25, 2019Aug 22, 2019Oct 27, 2019Feb 28, 2020Apr 28, 2020Aug 26, 2020Oct 28, 2020Mar 25, 2021Apr 22, 2021Jul 30, 2021Oct 27, 2021Apr 28, 2022Aug 12, 2022Oct 25, 2022Apr 21, 2023Aug 14, 2023Oct 30, 2023Apr 23, 2024Aug 17, 2024Oct 29, 2024Apr 24, 2025Aug 29, 2025Oct 30, 2025Apr 23, 2026Aug 11, 2026
EPS Estimate------------0.58-----------------
EPS Actual0.080.110.180.220.210.180.190.260.180.150.310.290.220.351.490.310.220.410.480.290.280.200.210.250.170.180.180.200.210.22
Surprise-------------62.07%-----------------
TimingPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-market-Pre-marketAfter-hours----

Key Statistics & Ratios

Market Cap12.94B
Enterprise Value11.59B
Trailing P/E58.26
Forward P/E0.00
Price / Sales6.12
Price / Book2.78
EPS0.95
Book Value19.60
Revenue (TTM)2.11B
Gross Profit (TTM)650.49M
EBITDA358.61M
Profit Margin9.97%
Operating Margin9.16%
Return on Equity5.14%
Return on Assets2.49%
Shares Outstanding233.81M
Shares Float180.64M
Beta0.55
Dividend Yield0.69%
Dividend Rate0.38
Payout Ratio60.38%

Dividends

20262×
0.10Aug 25, 20260.28Jun 10, 2026
20251×
0.28May 30, 2025
20241×
0.31Jun 14, 2024
20231×
0.10Jun 13, 2023
20221×
0.10Jun 13, 2022
20211×
0.08Apr 26, 2021
20201×
0.12Apr 29, 2020
20191×
0.15May 8, 2019
20181×
0.12May 18, 2018

Stock Splits

  • Apr 26, 20211.3:1
  • May 8, 20191.3:1
  • May 18, 20181.5:1